LICHENは,重鎖と実験的なニーズに条件付けられた軽鎖免疫グロブリン配列生成を可能にします
Henriette L Capel1, Isaac Ellmen1, Chris J Murray2
1Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, United Kingdom.
Communications biology
|February 21, 2026
まとめ
LICHENは,ヘビーチェーン情報に基づいて抗体光の配列を設計する新しいツールです. この計算によるアプローチは,治療用抗体開発の改善のために,機能的かつ多様なライトチェーンを生成することによって,抗体工学を支援します.
科学分野:
- バイオテクノロジー バイオテクノロジー
- 免疫学 免疫学とは
- コンピュータ生物学 コンピュータ生物学
背景:
- 治療用抗体の開発は,抗原結合における役割のため,重鎖配列を優先することが多い.
- しかし,適切な光鎖配列配列のペアリングは,抗体全体の機能に不可欠です.
研究 の 目的:
- LICHENは,重鎖情報に条件付けられた抗体光の配列を生成するためのコンピューティングツールです.
- 実験的な専門知識とコンピューティング能力を統合することによって,共同抗体設計を可能にします.
主な方法:
- LICHENは,与えられた重鎖に基づいて,有効で多様な抗体のような光配列を生成します.
- ツールはまた,生殖系とCDR情報を組み込み,望ましい性質のためのフィルター配列を組み込むことができます.
- 条件付け因子として重鎖と結合情報を用いて実験的検証が行われました.
主要な成果:
- インビトロ検証では,LICHENによって生成された配列が有効な発現率を示すことが確認されました.
- 生成された配列は,抗原結合能力を成功裏に保持しました.
- 計算によるアプローチは,抗体工学のシナリオで実現可能性を示した.
結論:
- LICHENは,抗体工学における効率的なライトチェーンペアリングを容易にする.
- このツールは,光配列のコンピューティング生成を活用して,治療用抗体の設計をサポートします.
- LICHENは,計算設計と実験的検証を組み合わせることで,抗体開発のワークフローを向上させます.
関連する概念動画
Antibody Structure
66.0K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
66.0K
Hybridoma Technology
17.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.9K
Antibody Structure and Classes
9.5K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
9.5K
B Cell Activation and Differentiation
17.2K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.2K


